(Q35671104)

9 August 2017

1 reference

title

Towards global consensus in the treatment of gastrointestinal stromal tumor (English)

1 reference

gastrointestinal stromal tumor

9 August 2017

1 reference

2

Jean-Yves Blay

0 references

Margaret von Mehren

series ordinal

3

object named as

Margaret von Mehren

1 reference

9 August 2017

Peter Reichardt

1

1 reference

9 August 2017

1 February 2010

1 reference

Expert Review of Anticancer Therapy

9 August 2017

1 reference

9 August 2017

10

1 reference

9 August 2017

2

1 reference

9 August 2017

221-232

1 reference

Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up.

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Molecular pathobiology of gastrointestinal stromal sarcomas.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

We should desist using RECIST, at least in GIST.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Gastrointestinal stromal tumors: pathology and prognosis at different sites

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Surgical considerations for gastrointestinal stroma tumor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

12 July 2018

Kit signal transduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451074

Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version

12 July 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.171

Diagnosis of gastrointestinal stromal tumors: A consensus approach

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20131998

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Complete hepatic resection of metastases from leiomyosarcoma prolongs survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20131998

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20131998

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1586/ERA.09.171

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

PubMed ID

20131998